Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
Angela George(Royal Marsden NHS Foundation Trust), Nazneen Rahman(Institute of Cancer Research), Zoe Kemp(Cancer Research UK), Helen Hanson(University of Exeter), Daniel Riddell(Institute of Cancer Research), Sabrina Talukdar(St George's, University of London), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ingrid Slade(Oxford University Hospitals NHS Trust), Ann Strydom(Institute of Cancer Research), Shazia Mahamdallie(Institute of Cancer Research), Sheila Seal(Institute of Cancer Research), Victoria Cloke(Institute of Cancer Research), Martin Gore(Imperial College London), Elise Ruark(Institute of Cancer Research)
Cited by 224
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k